A comprehensive view of astrazeneca ab. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Japan joins US, EU in approving AstraZeneca’s injectable asthma drug Tezspire tezepelumab, developed with Amgen; Tezspire treats severe, refractory bronchial asthma that can't be controlled with inhaled corticosteroids, long-term maintenance therapies
Published: September 28, 2022 by SeeNews Pharmaceuticals
AstraZeneca to end work on experimental cholesterol drug ION449 under development with partner Ionis; the two firms still working together on kidney drug ION532, fatty liver disease drugs ION839 and ION455, cancer therapy ION736
Published: September 26, 2022 by SeeNews Pharmaceuticals
AstraZeneca’s long-acting injectable COVID-19 antibody therapy Evusheld tixagevimab and cilgavimab receives approval in EU; drug treats patients who don’t require supplemental oxygen but are at increased risk to develop severe disease
Published: September 22, 2022 by SeeNews Pharmaceuticals
AstraZeneca reports EU advisory committee recommends its injectable Evusheld tixagevimab/cilgavimab antibody therapy for approval; treatment aimed at non-hospitalized COVID-19 patients who have increased risk for developing severe disease
Published: September 19, 2022 by SeeNews Pharmaceuticals
US District Court dismisses lawsuit brought against AstraZeneca by US shareholders; suit alleged AstraZeneca concealed problems with its COVID-19 vaccine that made the treatment unlikely to receive FDA approval
Published: September 13, 2022 by CE Noticias Financieras

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count